Anthropic drug-development partners + Mithril buy
Confirmed
Status
- Claim
Confirmed
- Our reporting
- High confidence
- Importance
- 3 of 5
- Last verified
- 28 October 2026
Your AI and this story
- GPT-6 Astra180 days after its cutoff
- Claude Opus 5.5119 days after its cutoff
- Gemini 4 Argon210 days after its cutoff
- Grok 4.7149 days after its cutoff
None of these four assistants can know about it. The closest, Claude Opus 5.5, stops 119 days before it.
Key facts
- Announced Oct 27, 2026 in an Anthropic research post with technical reports from each partner; @AnthropicAI’s post had about 2.05M views (fxtwitter, Oct 28)
- Partners and uses (Anthropic): Bristol Myers Squibb (assessing clinical-trial plans), Generate Biomedicines (cell-therapy redesign proposals), BigHat Biosciences (improving two antibody candidates), Divergence Labs (antibody design for food allergy), Enveda (manufacturing and regulatory documents), The Column Group (a new company, Pleiades, run with Claude to assess drug targets)
- Enveda (Anthropic’s figures): Claude reviewed 1,061 pages of manufacturing documentation, found all 11 issues human reviewers had found plus 7 more, and cut review time by 89% (over 25 hours to under 3)
- Mithril Medicine (Anthropic, R&D World): one-person company working on two rare forms of muscular dystrophy; founder Cody Tranbarger (Harvard MS/MBA 2025, ex-Prime Medicine, Casdin Capital, entrepreneur-in-residence at Atlas Venture) now works at Anthropic. Deal closed in July; terms not disclosed. Anthropic calls the model ‘Pipeline-in-a-Person’
- Mithril timeline (Anthropic): idea to promising mouse results in under 18 months with 11 external labs; a candidate could reach human trials ‘as soon as late 2028’
- Caveats (R&D World reading of the technical report): the mouse study compared 7 treated mice with 4 controls, assigned by litter without randomization; the report is ‘awaiting peer review’ and asks for blinded replication; of six Claude errors examined, at least three reached outside labs
- BMS’s Michael Pourdehnad (quoted by Anthropic): ‘Claude generated a robust initial analysis that helped inform our assessment of different development options’
- Reach: Hacker News front page (242 points, Oct 27); Endpoints News described the founder as a pseudonymous X poster (headline; paywalled)
Show 1 more
- Founder’s own account (X, Oct 27, ~1.2M views): Tranbarger was the pseudonymous @Prof_Oak_; Mithril develops bispecific antibodies for LAMA2-CMD, was seeded by Atlas Venture and run as ‘a single operator + a bunch of Claude (+ a stellar bench of part-time consultants)’; he calls the model ‘Pipeline-in-a-Person’
What happened
On Oct 27, 2026, the day after its public S-1, Anthropic described several months of research partnerships with six companies that develop medicines, and said it had begun drug-discovery work of its own. Each partner published a technical report. Most of the uses are in the paperwork and planning around drug development: reviewing manufacturing records, drafting regulatory documents, judging the odds of clinical-trial designs and assessing drug targets. Others proposed changes to candidate molecules that the partners then tested in their labs.
The same post disclosed that Anthropic had acquired Mithril Medicine, closed in July. Mithril’s only full-time employee, Cody Tranbarger, used Claude to run a programme for two rare muscular dystrophies with 11 contract labs. Anthropic says it went from idea to promising mouse results in under 18 months and could enter human trials as early as late 2028. Tranbarger now works at Anthropic. Endpoints News (paywalled, headline only) said Atlas Venture had backed Mithril.
Why it matters
It is the first time Anthropic has said it owns a drug programme, and it comes a week after OpenAI bought Orchestra Bio. Both labs are moving from selling models to life-sciences companies to running parts of drug development themselves. The figures come from Anthropic and its partners and have not been peer reviewed. R&D World’s reading of the Mithril report points to a small, non-randomized mouse study and to Claude errors that reached outside labs.
Sources
7 sources from 6 sites. Numbers match the chips in the text.
7 sources: 2 primary, 3 press, 2 reactions
Primary
- Anthropic: Early progress on accelerating drug development with Claudeanthropic.com, official
- Anthropic on X (2.05M views)x.com, official
Press
- R&D World: Anthropic acquires a one-person biotech that used Claude to coordinate 11 labsrdworldonline.com, press
- Endpoints News: Anthropic buys a single-person biotech startup backed by Atlas Ventureendpoints.news, press
- The Information: Anthropic buys a small drug startup as it pushes deeper into biotechtheinformation.com, press
Reactions
- Cody Tranbarger (@Prof_Oak_) on X: the Mithril reveal post (~1.2M views)x.com, discussion
- Hacker News discussion (242 points)news.ycombinator.com, discussion
Changes
- Added the founder’s reveal post (owner’s tip via @BithubPl)
- Filed (Anthropic post and fxtwitter read directly; R&D World read; Endpoints and The Information paywalled, headlines only)